Cargando…
Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials
Chimeric antigen receptor (CAR) redirected T-cells has shown efficacy in the treatment of B-cell leukemia/lymphoma, however, high numbers of relapses occur due to loss of targeted antigen or intrinsic failure of the CAR T-cells. In this situation modifications of the basic strategy are envisaged to...
Autores principales: | Ormhøj, Maria, Abken, Hinrich, Hadrup, Sine R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463290/ https://www.ncbi.nlm.nih.gov/pubmed/35199207 http://dx.doi.org/10.1007/s00262-022-03163-y |
Ejemplares similares
-
Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors
por: Abken, Hinrich
Publicado: (2021) -
Do Treg Speed Up with CARs? Chimeric Antigen Receptor Treg Engineered to Induce Transplant Tolerance
por: Kaljanac, Marcell, et al.
Publicado: (2022) -
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
por: Chmielewski, Markus, et al.
Publicado: (2013) -
Chimeric antigen receptors designed to overcome transforming growth factor‐β‐mediated repression in the adoptive T‐cell therapy of solid tumors
por: Hartley, Jordan, et al.
Publicado: (2019) -
Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle
por: Hombach, Andreas A., et al.
Publicado: (2013)